Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 3/20 | 0.49 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | STK25 | O00506 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400221 | 0.86 | P2RY14 (0.50) | P2RY14RETLCKSRCHTR1A | |
| SCHEMBL4401713 | 0.85 | GRM5 (0.39) | GRM5GAAALDH1A1NPC1RAB9A | |
| SCHEMBL4398705 | 0.84 | RAB9A (0.39) | HTR1AHTR1FGRM5GAAALDH1A1 | |
| SCHEMBL3833238 | 0.82 | P2RY14 (0.47) | P2RY14RETLCKSRCHTR1A | |
| SCHEMBL4398540 | 0.82 | ADORA3 (0.44) | P2RY14HTR1FGRM5GAAALDH1A1 | |
| SCHEMBL4792082 | 0.74 | CCNE1 (0.40) | P2RY14RETLCKSRC | |
| SCHEMBL4393075 | 0.72 | KDM4E (0.42) | HTR1AHTR1FGAAALDH1A1NPC1 | |
| SCHEMBL4397307 | 0.72 | HRH3 (0.41) | GAAALDH1A1 | |
| SCHEMBL4397301 | 0.72 | HRH3 (0.41) | GAAALDH1A1 | |
| SCHEMBL4394568 | 0.72 | HTR3A (0.42) | P2RY14RETHTR1AHTR1FNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| CN-101252935-A | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions containing them, and methods of their use | LEXICON GENETICS INC (US) | 2008-08-27 | — | — | CN | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | P2RY14 3461/4885RET 4670/4885LCK 3302/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | P2RY14 3056/4885RET 4669/4885LCK 1743/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | P2RY14 3825/4885RET 4484/4885LCK 3718/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | P2RY14 1188/4885RET 1981/4885LCK 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.